Bioavailability & Bioequivalence Studies

\r\n Bioavailability means the rate and extent to which the active drug substance or therapeutic moiety is absorbed from a pharmaceutical form and becomes available at the site of action. For drugs intended to exhibit a systemic therapeutic effect, bioavailability can be more simply understood as the rate and extent to which a substance or its therapeutic moiety is delivered from a pharmaceutical form into the general circulation. Bioequivalence focus on the release of a drug substance from a drug product and subsequent absorption into systemic circulation. Bioequivalence studies are a surrogate marker for clinical effectiveness and safety data as it would not normally be practical to repeat clinical studies for generic products.

\r\n
    \r\n
  • \r\n Invitro bioequivalence
  • \r\n
  • \r\n Bioavailability metrics
  • \r\n
  • \r\n Waiver of invivo bioavailability
  • \r\n
  • \r\n Bioequivalence study protocols
  • \r\n
  • \r\n Genetic phenotyping
  • \r\n
  • \r\n Bioequivalence study design
  • \r\n
\r\n

\r\n  

\r\n

    Related Conference of Bioavailability & Bioequivalence Studies

    Bioavailability & Bioequivalence Studies Conference Speakers